A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

NCT ID: NCT05697055

Last Updated: 2023-02-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 410 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-21
• Study Completion Date: 2023-07-21

Brief Summary

The COVID-19 pandemic has become a major public health challenge, and the treatment options for the disease are currently limited. The commonly used oral small-molecule anti-COVID-19 drugs in China are Nirmatrelvir-Ritonavir and Azvudine. These drugs have been tested in pre-marketing clinical trials in patients with non-severe COVID-19 infection and have demonstrated therapeutic effects in inhibiting virus transmission and preventing disease progression. However, until now, the efficacy and safety of these drugs in patients with moderate to severe COVID-19 infections remains unclear. Therefore, this study is aiming to compare the efficacy and safety of Azvudine and Nirmatrelvir-Ritonavir in moderate to severe COVID-19 infections. This study will be a multicenter, randomized, controlled clinical trial study in patients hospitalized with moderate to severe COVID-19 infections. Recovery of clinical symptoms, nucleic acid negative conversion, improvement in oxygenation index, and imaging improvement will be used as study endpoints.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Azvudine

Group Type: EXPERIMENTAL

Azvudine

Intervention Type: DRUG

5mg orally, once a day, for no more than 14 days

Nirmatrelvir-Ritonavir

Group Type: ACTIVE_COMPARATOR

Nirmatrelvir-Ritonavir

Intervention Type: DRUG

Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days

Interventions

Azvudine

5mg orally, once a day, for no more than 14 days

Intervention Type: DRUG

Nirmatrelvir-Ritonavir

Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Hospitalized patients of ≥18 years old, regardless of gender or race;

2. Patients who have a positive SARS-CoV-2 test result;

3. Diagnosed with moderate or severe COVID-19 infection according to the diagnostic criteria from the "Diagnosis and treatment program trial version 10 guidelines" issued by the National Health Commission of the People's Republic of China. Including:

①Moderate: continuous high fever for more than 3 days or/and cough, shortness of breath, etc., but the breathing frequency (RR) is less than 30 times/minute, and the oxygen saturation when inhaling air at rest is > 93%. Imaging shows the characteristic manifestations of COVID-19 pneumonia.

② Severe: Adults meet any of the following requirements: A, shortness of breath, RR≥ 30 times/minute; B, the oxygen saturation when inhaling air at rest is ≤ 93%; C, Arterial partial oxygen pressure (PaO2)/ Fraction of inspiration O2 (FiO2) ≤300mmHg (1mmHg=0.133kPa), and PaO2/FiO2 should be corrected according to the following formula for areas above 1000 m :PaO2/FiO2× [760/ atmospheric pressure (mmHg)]; D, the clinical symptoms were gradually aggravated, and the lung imaging showed that the lesion progressed significantly within 24 ~ 48 hours > 50%.

4. Join this study voluntarily.

5. Each subject must sign an informed consent form (ICF) indicating that he/she understands the purpose and procedure of the study and is willing to participate in the study. Considering the patient's condition, the ICF may be signed by the legal representative.

Exclusion Criteria

1. Allergic to the drugs involved;

2. Pregnancy or lactation;

3. Diagnosed or suspected critical COVID-19 infection;

4. Child-Pugh C of liver function or estimated glomerular filtration rate (eGFR) less than 30mL/min during screening;

5. Receive SARS-CoV-2 monoclonal antibody therapy or other antiviral therapy;

6. The subject and/or authorized family members refused to receive anti-COVID-19 treatment;

7. Any life-threatening disease or organ system dysfunction that the researcher thinks can harm the safety of the subjects and expose the research results to unnecessary risks; drug addicts, uncontrolled mental illness or cognitive dysfunction.

8. Join other similar clinical researchers within 3 months;

9. Patients who were not considered suitable for inclusion by the researchers (such as patients who were expected to be unable to adhere to the treatment due to financial problems).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qianfoshan Hospital

OTHER

Sponsor Role: collaborator

The Second Affiliated Hospital of Shandong First Medical University

OTHER

Sponsor Role: collaborator

The Affiliated Hospital Of Southwest Medical University

OTHER

Sponsor Role: collaborator

Gansu Provincial Hospital

OTHER

Sponsor Role: collaborator

Rizhao People's Hospital

OTHER

Sponsor Role: collaborator

Shandong Provincial Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Jia-jun Zhao

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Shandong Provincial Hospital

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Bing Leng

Role: CONTACT

taozilb@163.com

+86531-68776461

Chengwu Shen

Role: CONTACT

scw810@163.com

+86531-68778252

Other Identifiers

SWYX2023022

Identifier Type: -

Identifier Source: org_study_id